Pharmaceutical Commerce - January/February 2016

Managing logistics partnerships in uncertain times

February 02, 2016

Outsourced services can provide significant financial and risk-avoidance benefits

Logistics providers confront a complex, global healthcare market

February 02, 2016

The rise in product volume is more than matched by the rise of regulatory constraints

Digitized stress analysis improves blister performance

February 02, 2016

Design analysis can dictate blister composition

Pharma logistics--so what?

February 02, 2016

Looking at the essential value of well-managed supply chains

Industry hit a record low number of FDA OPDP actions in 2015

February 01, 2016

Office of Prescription Drug Promotion finds little to complain about

Collaboration key to a healthy supply chain in 2016

February 01, 2016

HDMA seeks to encourage more outreach to business partners and government

Pharma's bread and butter is still made with powder

February 01, 2016

Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay

Problems continue with FDA postmarketing review processes

January 15, 2016

Industry is doing better at filing studies, but the agency is falling behind reviews, says GAO

New life sciences capital-construction projects totaled $15 billion in 2015

January 12, 2016

Construction index shows a steady level of North American activity

New year, new names for BIO and Canada's pharma trade association, and more

January 06, 2016

'Innovation' is the recurring theme

Full-line distributor sales reached $350 billion in 2013, representing 91% of pharma sales

January 05, 2016

HDMA's 2015-16 Factbook updates member financial, operational performance

Mind your "Q"s: QPharma acquires Qforma

January 05, 2016

Combination expands breadth of commercialization and compliance services

FDA approved 45 new drugs in 2015--a new recent record

January 04, 2016

List includes 21 new orphan drugs, and of the 45, 15 are cold chain products

Eagle Pharmaceuticals gets a 505(b)(2) approval for docetaxel

December 28, 2015

Company partners with Teikoku for the latter's first marketed oncology product, and earns a milestone payment from Teva